Skip to main content
NUWE logo

Nuwellis, Inc. (NUWE) Stock Price & Analysis

Nuwellis, Inc. (NUWE) — MoonshotScore 20/100 (Weak band), calculated Nov 18, 2026. Price $3.81 (-2.06%), as of the Nov 19, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$3.81 −$0.08 (-2.06%)

Nuwellis, Inc. · NUWE

Nuwellis, Inc. is a medical device company specializing in ultrafiltration therapy, offering Aquadex FlexFlow and Aquadex SmartFlow systems for patients with fluid overload resistant to diuretics. The company distributes its products through a direct salesforce in the United States and independent distributors across numerous international markets.

Price as of Nov 19, 2026

Key Statistics

20 of 100

MoonshotScore v2 · Nuwellis (NUWE)

Weak
Business Quality Thin (20)
Financial Safety Okay (45)
Valuation Fair (68)
Growth Durability Fading (31)
Momentum Falling (14)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality and weak growth, though the balance sheet is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Okay; Valuation: Fair; Growth Durability: Fading; Momentum: Falling.

  • quarterly revenue $2M (Q3 FY2026, quarter ended Sep 30, 2026)
  • EPS beat 4 of the last 8 reports
  • Altman Z -35.10 · Piotroski F 4

Holding back: weak fundamentals, soft growth, weak price trend

Helping: an attractive price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for NUWE (57 recorded, newest six shown)
RecordedScoreBand
19Weak
19Weak
19Weak
19Weak
20Weak
20Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$3.81
Change on the day-2.06%
52-week range$2.52 – $1556.10
Shares traded on the day9.4K

Price & events

Other perspectives

Council score for Nuwellis (NUWE): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Neutral
Valuation Moderate
Growth Durability Weak
Momentum Negative

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Moderate
ROE Negative
Gross Margin Strong

Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Nuwellis (NUWE), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Nuwellis, Inc. (NUWE) is the company analyzed here. It employs 38 people and is led by Michael McCormick. In Q3 FY2026 it reported revenue of $2M and net income of -$2M.

2 · Latest results

What do the latest results show for Nuwellis (NUWE)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $2M. Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$2M-$2M-$5.81 (diluted)
Q2 FY2026$2M-$5M-$239.76 (diluted)
Q1 FY2026$2M-$4M-$658.35 (diluted)
Q4 FY2025$2M-$2M-$472.50 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Nuwellis (NUWE)?

Short answer · as of

The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is weak fundamentals, soft growth, weak price trend. The distress and quality screens read Altman Z -35.10 · Piotroski F 4. Trailing ratios: current ratio 3.99.

5 · Peer comparison

How does Nuwellis compare with its peers?

Short answer

Nuwellis's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Edwards Lifesciences Corporation (EW) Same industry, near in market value$105.23 Nov 18, 2026$60.5B93 5-pillar Nov 18, 2026
DexCom, Inc. (DXCM) Same industry, near in market value$80.19 Nov 19, 2026$29.9B93 5-pillar Nov 18, 2026
Penumbra, Inc. (PEN) Same industry, near in market value$320.00 Nov 19, 2026$12.6B92 5-pillar Nov 18, 2026
STERIS plc (STE) Same industry, near in market value$259.57 Nov 18, 2026$25.2B87 5-pillar Nov 18, 2026
Insulet Corporation (PODD) Same industry, near in market value$139.98 Nov 18, 2026$9.71B85 5-pillar Nov 18, 2026
Smith & Nephew plc (SNN) Same industry, near in market value$29.83 Nov 19, 2026$12.5B84 5-pillar Nov 18, 2026
Align Technology, Inc. (ALGN) Same industry, near in market value$163.96 Nov 18, 2026$11.6B83 5-pillar Nov 18, 2026
Medtronic plc (MDT) Same industry, near in market value$100.72 Nov 18, 2026$129B81 5-pillar Nov 18, 2026
Stryker Corporation (SYK) Same industry, near in market value$318.15 Nov 18, 2026$121B80 5-pillar Nov 18, 2026
Zimmer Biomet Holdings, Inc. (ZBH) Same industry, near in market value$101.47 Nov 19, 2026$19.2B79 5-pillar Nov 18, 2026
Koninklijke Philips N.V. (PHG) Same industry, near in market value$29.27 Nov 19, 2026$28.6B78 5-pillar Nov 18, 2026
Boston Scientific Corporation (BSX) Same industry, near in market value$42.99 Nov 19, 2026$62.3B77 5-pillar Nov 18, 2026
Nuwellis (NUWE) — this page$3.81—20

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held NUWE in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported NUWE in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Nuwellis (NUWE)

These answers are editorial: 1 of these 9 answers is drawn from the NUWE research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for NUWE?

NUWE carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is NUWE a good stock to buy?

Stock Expert AI does not rate NUWE buy, sell or hold. Nuwellis, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the NUWE stock price today?

The last price recorded for Nuwellis, Inc. (NUWE), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key growth opportunities for NUWE in healthcare?

Nuwellis, Inc. has several key growth opportunities within the healthcare sector. One significant avenue is the expansion into new geographic markets, leveraging its existing international distribution network to reach more countries where fluid overload is a prevalent issue.

What are the key factors to evaluate for NUWE?

Nuwellis, Inc. (NUWE) holds a MoonshotScore in the low range. Not financial advice.

How frequently does NUWE data refresh on this page?

NUWE's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven NUWE's recent stock price performance?

Nuwellis, Inc. (NUWE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product portfolio addressing a critical unmet medical need in fluid overload. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider NUWE overvalued or undervalued right now?

Nuwellis, Inc. (NUWE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research NUWE before investing?

Before investing in Nuwellis, Inc. (NUWE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.